Reproxalap

Reproxalap (ADX-102) is an active aldehyde sequestering agent. Reproxalap reduces the PKCα activity. Reproxalap blocks caspase 3/7 activation. Reproxalap protects cells from the cytotoxicity of C18:0-al. Reproxalap has anti-inflammatory and pain-relieving effects. Reproxalap is used in studies of dry eye, allergic conjunctivitis, and non-infectious anterior uveitis^{[1][2][3][4][5]}. In Vitro: Reproxalap (1 μM-10 mM; 1-24 h) causes a significant decrease in the viability of BEAS-2B and 16HBE cells, and dose-dependently reverses the slowing of BEAS-2B cell migration induced by 5% cigarette smoke extract^[1].
Reproxalap (100-300 μM; 24 h) protects FAA-K1A cells from the cytotoxicity of C18:0-al^[2].
In Vivo: Reproxalap (30-100 mg/kg, once or twice a day) shows a dose-dependent reduction in pain-related behaviors in acute pain models^[3].
Reproxalap (10 mg/kg, intraperitoneal injection, single dose) significantly reduces the formation of N-retinyl-phosphatidylethanolamine (A2E) in the retinas of mice with macular degeneration^[5].
Reproxalap (25-50 μg, IVT, injected in five doses after LPS (HY-D1056) induction) can improve eye scores in uveitis rats^[5].